Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...

Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...

Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...